Profluent is at the forefront of biological innovation, leveraging AI to design proteins that revolutionize medicine, agriculture, and beyond. Our platform specializes in creating new biology through AI-authored proteins, enabling breakthroughs in various fields. By combining machine learning and biology, we partner to solve complex challenges, offering AI-generated solutions for therapeutics, industrial enzymes, and more.
We're tracking Profluent's market expansion
How Profluent's international expansion compares to its competitors
ProfluentYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ProfluentYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
Profluent × Eli Lilly
Ended
Today we announced a landmark partnership with Eli Lilly and Company to use our AI models to design recombinases for genetic medicine—a collaboration valued at up to $2.25 billion before royalties.The goal: use Profluent's AI models to design recombinase editors capable of inserting long stretches of DNA at precise locations in the genome.Many genetic diseases involve hundreds of different mutations across patients–no single edit can address them all. Inserting a complete functional gene with a ...
EndedProfluent, an AI protein design leader, secured $106M in funding co-led by Altimeter Capital and Bezos Expeditions, with participation from existing investors.
Profluent Bio raised $106M from investors including Jeff Bezos to accelerate AI-driven protein design, aiming to make biology more programmable.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Profluent's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
